Recent progress in antiviral chemotherapy for respiratory syncytial virus infections

Bibliography

• KIM H-W, ARROBIO JO, BRANDT CD et al.: Epidemiologyof respiratory syncytial virus infection in Washington, D.C. 1. Importance of the virus in different respiratory tract disease syndrome and temporal distribution of infection. Am. J. Epidemiol. (1973) 98:216–225.
   Google Scholar
• PARROT RH, KIM H-W, ARROBIO JO et al.: Epidemiologyof respiratory syncytial virus infection in Washington, D.C. 2. Infection and disease with respect to age, immunologic status, race and sex. Am. J. Epidemic)]. (1973) 98:289–300.
   Google Scholar
• GILCHRIST S, TOROK TJ, GARRY HE, ALEXANDER JPANDERSON LJ: National surveillance for respiratory syncytial virus, United States, 1985-1990. J. Infect. Dis. (1994) 170:986–990.
   PubMed Web of Science ®Google Scholar
• TYERYAR FJ: Report of a workshop on respiratory syncytial virus and parainfluenza viruses. J. Infect. Dis. (1983) 148:588–598.
   PubMed Web of Science ®Google Scholar
• GLEZEN WP, PAREDES A, ALLISON JE, TABER LH, FRANK AL: Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. J. Pediatr. (1981) 98:708–715.
   PubMed Web of Science ®Google Scholar
• KIM W-K, CANCHOLA G, BRANDT CD et al: Respiratory syncytial virus disease in infants despite prior admini-stration of antigenic inactivated vaccine. A. J. Epidemic)]. (1969) 89:422–434.
   PubMed Web of Science ®Google Scholar
• •There is no useful vaccine against RSV infection.
   Google Scholar
• GROOTHUIS JR, KING SJ, HOGERMAN DA, PARADISO PR,SIMOES EAF: Safety and immunogenicity of a purified respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. (1998) 177:467–469.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD SS, FIREDTONE C-Y, KARRON RA et al:Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Vim]. (1999) 73:871–877.
   Web of Science ®Google Scholar
• CHANOCK R, ROIZMAN B & MYERS R: Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCM. 1. Isolation, proper-ties and characterization. Am] Hyg. (1957) 66:281–290.
   Google Scholar
• COLLINS PL, MCINTOSH K & CHANOCK RM: Respiratory syncytial virus. In: Fields Virology (3rd Edition). BN Fields, DM Knipe, Howley PM (Eds.), Lippincott-Raven, Philadel-phia, USA (1997):1313–1351
   Google Scholar
• SUDO K, WATANABE W, MORI S, KONNO K, SHIGETA S,YOKOTA T: Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo. Anti vir. Chem. Chemother. (1999) 10:135–139.
   PubMed Web of Science ®Google Scholar
• MACDONALD NE, HALL CB, SUFFIN SC, ALEXON C, HARRIS PJ, MANNING JA: Respiratory syncytial viral infection in infants with congenital heart disease. N Engl. J. Med. (1982) 307:397–400.
   PubMed Web of Science ®Google Scholar
• ••The mortality of RSV infection in high risk group is veryhigh.
   Google Scholar
• HARRINGTON RD, HOOTON TM, HACKMAN RC et al: Anoutbreak of respiratory syncytial virus in a bone marrow transplant center. J. Infect. Dis. (1992) 165:987–993.
   PubMed Web of Science ®Google Scholar
• ENGLUND JA ANDERSON LJ, RHAME FS: Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J. Clin. Microbiol. (1991) 29:115–119.
   PubMed Web of Science ®Google Scholar
• POHL C, GREEN M, WALD ER, LEDESMA-MEDINA J: Respiratory syncytial virus infections in pediatric liver transplant recipients. J. Infect. Dis. (1992). 165:166–169.
   PubMed Web of Science ®Google Scholar
• OGRA PL & PATEL J: Respiratory syncytial virusinfection and the immunocompromised host. Pediatr. Infect. Dis. J. (1988) 7:246–249.
   PubMed Web of Science ®Google Scholar
• GROOTHUIS JR, GUITIERREZ KM, LAUER BA: Respira-tory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics (1988) 82:199–203.
   PubMed Web of Science ®Google Scholar
• TISSING WJE, VAN STEENSEL-MOLL HA, OFFRINGA M: Risk factors for mechanical ventilation in respiratory syncytial virus infection. Eur. J. Pediatr. (1993) 152:125–127.
   PubMed Web of Science ®Google Scholar
• HIATT PW, GRACE SC, KOZINETZ CA et al.: Effect of virallower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics (1999) 103:619–626.
   PubMed Web of Science ®Google Scholar
• HEIKKINEN T, THINT M, CHONMAITREE T: Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl. J. Med. (1999) 340:260–264.
   PubMed Web of Science ®Google Scholar
• LARKIN M: Respiratory viruses implicated in develop-ment of otitis media. Lancet (1999) 353:473–473.
   Web of Science ®Google Scholar
• STEIN RT, SHERRILL D, MORGAN WJ et al.: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet (1999) 354:541–545.
   PubMed Web of Science ®Google Scholar
• EVERARD ML: What link between early respiratory viral infections and atopic asthma? Lancet (1999) 354:527–528.
   PubMed Web of Science ®Google Scholar
• FOUILLARD L, MOUTHON L, LAPORTE JP et al.: Severerespiratory syncytial virus pneumonia after autolo-gous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplantation (1992) 9:97–100.
   PubMed Web of Science ®Google Scholar
• •RSV infection is serious in the elderly as well.
   Google Scholar
• FALSEY AR, CUNNINGHAM CK, BARKER WH et al.: Respirtory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. (1995) 172:389–394.
   PubMed Web of Science ®Google Scholar
• AGUIS G, DINDINAUD G, BIGGER RJ et al.: An epidemicof respiratory syncytial virus in elderly people: clinical and serological findings. J. Med. Vim]. (1990) 30:117–127.
   PubMed Web of Science ®Google Scholar
• ENGLUND JA, SULLIVAN CJ, JORDAN MC, DEHNER LP,VERCELLOTTI GM, BALFOUR HH: Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. (1988) 109:203–208.
   PubMed Web of Science ®Google Scholar
• HAN LL, ALEXANDER JP, ANDERSON LJ: Respiratory syncytial virus pneumonia among the elderly: An assessment of disease burden. J. Infect. Dis. (1999) 179:25–30.
   PubMed Web of Science ®Google Scholar
• GUIDRY GG, BLACK-PAYNE CA, PAYNE KD, JAMISON RM, GEORGE RB, BOCCHINI JA: Respiratory syncytial virus infection among intubated adults in a university medical intensive care unit. Chest (1991) 100:1377–1384.
   PubMed Web of Science ®Google Scholar
• HEALTH AND WELFARE STATISTICS ASSOCIATION: Themortality rates of diseases in 1997. J. Health & Welfare Statistics (Kousei no Shihyou, in Japanese) (1999) 46:412–413.
   Google Scholar
• ANSARI SA, SPRINGTHORPE VS, SATTAR SA, RIVARD S,RHAMAN M: Potential role of hands in the spread of respiratory viral infections: studies with human parainfluenza virus 3 and rhinovirus 14. J. Clin. Microbiol. (1991) 29:2115–2119.
   PubMed Web of Science ®Google Scholar
• GALA CL, HALL CB, SCHNABEL KC et al: The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection. J. Am. Med. Assoc. (1986) 256:2706–2708.
   Web of Science ®Google Scholar
• •The use of eye-nose goggle is prophylactic for the nosocomial RSV infection.
   Google Scholar
• LECLAIR JM, FREEMAN J, SULLIVAN BF, CROWLEY CM, GOLDMAN DA: Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl. J. Med. (1987) 317:329–334.
   PubMed Web of Science ®Google Scholar
• MADGE P, PATON JY, MCCOLL JH, MACKKIE PLK: Prospective controlled studu of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet (1992) 340:1079–1082.
   PubMed Web of Science ®Google Scholar
• O'CALLAGHAN CA: Prevention of nosocomial respira-tory syncytial virus infection. Lancet (1993) 341:182–182.
   Google Scholar
• GILBERT BE, KNIGHT V: Biochemistry and clinical application of ribavirin. Antimicrob. Agents Chemother. (1986) 30:201–205.
   PubMed Web of Science ®Google Scholar
• PATTERSON JL, FRENANDEZ-LARSSON R: Molecular mechanism of action of ribavirin. Rev. Infect. Dis. (1990) 12:1139–1145.
   PubMedGoogle Scholar
• ••Ribavirin is the only approved drug for RSV infections.
   Google Scholar
• COMMITTEE ON INFECTIOUS DISEASES: Ribavirin therapy of respiratory syncytial virus. Pediatrics (1987) 79:475–478.
   PubMed Web of Science ®Google Scholar
• HEROZOG KD, LONG SS, MCGUIGAN M, FISHER MC, DEFOREST A: Impact of treatment guidelines on use of ribavirin. Am. J. Dis. Child. (1990) 144:1001–1004.
   PubMedGoogle Scholar
• ENGLUND JA, PIEDRA PA, JEFFERSON LS, WILSON SZ,TABER LH, GILBERT BE: High-dose, short duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. (1990) 117:313–320.
   PubMed Web of Science ®Google Scholar
• LEWINSOHN DM, BOWDEN RA, MATTSON D, CRAWFORD SW: Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob. Agents Chemother. (1996) 40:2555–2557.
   PubMed Web of Science ®Google Scholar
• SNELL NJC: Economic and long-term benefits of ribavirin therapy on respiratory syncytial virus infection. Lung (1990) (Suppl.):422–429.
   Google Scholar
• WYDE PR: Respiratory syncytial virus (RSV) disease and prospects for its control. Antivir. Res. (1998) 39:63–79.
   PubMed Web of Science ®Google Scholar
• HALL CB, KOPELMANAE, DOUGLAS RG, GEIMAN JM, MEAGHER MP: Neonatal respiratory syncytial virus infection. N Engl. J. Med. (1979) 300:393–396.
   PubMed Web of Science ®Google Scholar
• PRINCE GA, HEMMING VG, HOSWOOD RL, BARON PA,CHANOCK RM: Effectiveness of topically administrated neutralizing antibodies in experimental immuno-therapy of respiratory syncytial infection in cotton rats. J. Virol. (1987) 61:1851–1854.
   PubMed Web of Science ®Google Scholar
• SIBER GR, LESZCZYNSKI J, PENA-CRUZ V etal.: Protectiveactivity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J. Infect. Dis. (1992) 165:456–463.
   Google Scholar
• JOHNSON S, OLIVER C, PRINCE GA et al: Developmentof a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. (1997) 176:1215–1224.
   PubMed Web of Science ®Google Scholar
• FISHER RG, JOHNSON JE, DILLON SB, PARKER RA, GRAHAM BS: Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppress the native antibody response but does not impair to late rechallenge. J. Infect. Dis. (1999) 180:708–713.
   PubMed Web of Science ®Google Scholar
• THE PREVENT STUDY GROUP: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics (1997) 99:93–99.
   PubMed Web of Science ®Google Scholar
• THE IMPACT-RSV STUDY GROUP: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics (1998) 102:531–537.
   PubMed Web of Science ®Google Scholar
• ••A humanised mAb reduced hospitalisation from RSVinfection.
   Google Scholar
• EVERITT DE, DAVIS CB, THOMPSON K et al.: Thepharmacokinetics, antigenicity and fusion-inhibition activity of RSH-Z19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J. Infect. Dis. (1996) 174:463–469.
   PubMed Web of Science ®Google Scholar
• JOHNSON S, GRIEGO D, PFARR DS et al.: A directcomparison of the activities of two humanized respira-tory syncytial virus monoclonal antibodies: MEDI-493 and RSH-Z19. J. Infect. Dis. (1999) 180:35–40.
   PubMed Web of Science ®Google Scholar
• •See reference [50] for annotation.
   Google Scholar
• SIMOES EAF, GROOTHUIS JR, TRISRAM DA et al: Respira-tory syncytial virus-enriched globulin for the preven-tion of acute otitis media in high-risk children. J. Pediatr. (1996) 129:214–219.
   PubMed Web of Science ®Google Scholar
• MALLEY R, DEVINCENZO J, RAMINO 0 et al.: Reductionof respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. (1998) 178:1555–1561.
   Google Scholar
• KAWANA F, SHIGETA, S, HOSOYA M, SUZUKI H, DE CLERCQ E: Inhibitory effect of antiviral compounds on respiratory syncytial virus replication in vitro. Antimi-crob. Agents Chemother. (1987) 31:1225–1230.
   PubMed Web of Science ®Google Scholar
• SHIGETA S, MORI S, BABA M et al: Antiviral activites ofribavirin, 5-ethyny1-1-b-u-ribofuranosylimidazole-4--carboxamide and 6'- (R)-6'-C-methylneplanocin A against several ortho- and parmyxoviruses. Antimi-crob. Agents Chemother. (1992) 36:435–439.
   PubMed Web of Science ®Google Scholar
• •Several nucleoside analogues, polyoxometalates and benzoditiin were shown to be inhibitory against RSV growth in vitro.
   Google Scholar
• KOSUGI Y, SAITO Y, MORI S, WATANABE J, BABA M,SHIGETA S: Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho- and paramyxoviruses. Antivir. Chem. Chemother. (1994) 5:366–371.
   Web of Science ®Google Scholar
• JAIRATH A, VARGAS PB, HAMLIN HA, FIELD AK, KILKUSKIE RE: Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antivir. Res. (1997) 33:201–213.
   PubMed Web of Science ®Google Scholar
• BARNARD DL, SIDWELL PW, XIAO W, PLAYER MR, ADAHSA, TORRENCE PF: 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antivir. Res. (1999) 41:119–134.
   PubMed Web of Science ®Google Scholar
• TORRENCE PF, MAITRA RK, LESIAK K, LHAMNEI S, ZHOUA, SILVERMAN RH Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera. Proc. Natl. Acad. ScL USA (1993) 90:1300–1340.
   PubMed Web of Science ®Google Scholar
• SAUER G, AMTMANN E, MELBER K et al.: DNA and RNAvirus species are inhibited by xanthates, a class of antiviral compounds with unique properties. Proc. Natl. Acad. ScL USA (1984) 81; 3263–3267.
   PubMed Web of Science ®Google Scholar
• VILLANUEVA N, NAVARRO J, CUBERO E: Antiviral effectsof xanthate D609 on the human respiratory syncytial virus growth cycle. Virology (1991) 181:101–108.
   PubMed Web of Science ®Google Scholar
• RICHARD J, PELLOUX H, GROSS U, MEUNIER A, AMBROISE-THOMAS P: Induction of Toxoplasma gondii cystogenesis and multiplication arrest by treatments with a phosphatidylcholine-specific phospholipase C inhibitor. J. ParasitoI (1999) 85:583–585.
   PubMed Web of Science ®Google Scholar
• KIM GS, JUDD DA, HILL CL, SCHINAZI RF: Synthesis,characterization and biological activity of a new potent class of anti-HIV agents, the peroxoniobium-substituted heterpolytungstates. J. Med. Chem. (1994) 37:816–820.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO N, SCHOLS D, DE CLERCQ E et al.: Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. Mel. Pharmacol. (1992) 42:1109–1117.
   Google Scholar
• IKEDA S, NISHIYA S, YAMAMTO A, YAMASE T, NISHIMURA C, DE CLERCQ E: Activity of the Keggin polyoxometalate PM-19 against herpes simplex virus Type 2 infection in immunosuppressed mice: Role of peritoneal macrophage activation. J. Med. Vim]. (1993) 41:191–195.
   PubMed Web of Science ®Google Scholar
• SHIGETA S, MORI S, WATANABE J et al.: In vitroantimyxovirus and anti-human immunodeficiency virus activities of polyoxometaltes. Antivir. Chem. Chemother. (1995) 6:114–122.
   Web of Science ®Google Scholar
• •See reference [56] for annotation.
   Google Scholar
• SHIGETA S, MORI S, WATANBE J, YAMASE T, SCHINAZI RF: In vitro anti-myxovirus activity and mechanism of anti-influenza activity of polyoxometalates PM-504 and PM-523. Antivir. Chem. Chemother. (1996) 7:346–352.
   Web of Science ®Google Scholar
• BARNARD DL, HILL CL, GAGE T et al.: Potent inhibition of respiratory syncytial virus by polyoxometalates of several structure classes. Antivir. Res. (1997) 34:27–37.
   PubMed Web of Science ®Google Scholar
• WYDE PR, MEYERSON LR, GILBERT BE: An in vitro evaluation of the antiviral activity of SP-303, an Euphorbiaceare shrub extract, against a panel of respiratory viruses. Drug Dev. Res. (1993) 28:467–472.
   Web of Science ®Google Scholar
• BERNARD DL, SMEE DF, HUFFMAN JH, MEYERSON LR, SIDWELL RW: Anti-herpesvirus activity and mode of action of SP-303, a novel plant flavonoid. Chemotherapy (1993) 19:1–9.
   Google Scholar
• GILBERT BE, WIDE PR, WILSON SZ, MEYERSON LR: SP-303 small particle aerosol treatment of influenza A virus infection in mice and reppiratory syncytial virus infection iin cotton rats. Antivir. Res. (1993) 21:37–45.
   PubMed Web of Science ®Google Scholar
• WIDE PR, AMBROSE MW, MEYERSON LR, GILBERT BE: The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parinflu-enza type 3 viruses in cotton rats. Antivir. Res. (1993) 20:145–154.
   PubMed Web of Science ®Google Scholar
• WILD C, GREENWELL T, MATTHEWS T: A synthetic peptide from 11IV-1 GP-41 is a potent inhibitor of virus mediated cell-cell fusion. AIDS Res. Hum. Retrovir. (1993) 9:1051–1053.
   PubMed Web of Science ®Google Scholar
• •Synthetic peptides mimic to the parts of fusion protein of RSV and HIV were shown to be inhibitory for virus fusion.
   Google Scholar
• LAMBERT DM, BARNEY S, LAMBERT AL et al.: Peptides from conserved region of paramyxovirus fusion proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. USA (1996) 93:2186–2191.
   PubMed Web of Science ®Google Scholar
• ••See reference [74] for annotation.
   Google Scholar
• RYAN C, MO J, SCHLESINGER J: Antiviral activity of peptide with sequences related to the cytoplasmic domain of the respiratory syncytial virus glycopro-teins. Antivir. Chem. Chemother. (1995) 6:391–397.
   Web of Science ®Google Scholar
• WATANABE W, SUDO K, SATO R et al.: Novel anti-respirtory syncytial (RS) viral compounds: benzodithiin derivatives. Biochem. Biophys. Res. Commun. (1998) 249:922–926.
   PubMed Web of Science ®Google Scholar
• SUDO K, WATANABE W, KONNO K et al.: Efficacy of DR3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob. Agents Chemother. (1999) 43:752–757.
   PubMed Web of Science ®Google Scholar
• •See reference [56] for annotation.
   Google Scholar